The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma

被引:19
作者
Yoong, Y [1 ]
Porrata, LF [1 ]
Inwards, DJ [1 ]
Ansell, SM [1 ]
Micallef, INM [1 ]
Litzow, MR [1 ]
Gertz, MA [1 ]
Lacy, MQ [1 ]
Dispenzieri, A [1 ]
Gastineau, DA [1 ]
Tefferi, A [1 ]
Elliott, M [1 ]
Snow, DS [1 ]
Hogan, WJ [1 ]
Markovic, SN [1 ]
机构
[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 55909 USA
关键词
kinetics of absolute lymphocyte count recovery; autologous stem cell transplantation; non-Hodgkin's lymphoma;
D O I
10.1080/10428190500126380
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Absolute lymphocyte count (ALC) >= 500 cells/mu l at day 15 after autologous stem cell transplantation (ASCT) is a powerful independent, prognostic indicator for survival in multiple hematological malignancies. A limitation in these studies was the selection of a single time point (day 15 post-ASCT) as the only discriminator of clinical outcome in relation to ALC recovery. We hypothesized there is a continuous and not discrete relationship between ALC recovery and clinical outcome post-ASCT in NHL. Therefore, we analyzed 274 consecutive patients who underwent ASCT for NHL between 1987 and 2001. The primary end point was to assess the impact of the kinetics of post-ASCT lymphocyte recovery >= 500 cells/mu l (K-ALC) on overall survival ( OS) and progression-free survival (PFS). K-ALC was a predictor of OS and PFS when the Cox proportional hazards model was used with K-ALC entered as a continuous variable ( p < 0.0001). Multivariate analysis demonstrated K-ALC recovery post-ASCT to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL.
引用
收藏
页码:1287 / 1294
页数:8
相关论文
共 34 条
[1]  
ACKERSTEIN A, 1991, BLOOD, V78, P1212
[2]   Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors [J].
Bomberger, C ;
Singh-Jairam, M ;
Rodey, G ;
Guerriero, A ;
Yeager, AM ;
Fleming, WH ;
Holland, HK ;
Waller, EK .
BLOOD, 1998, 91 (07) :2588-2600
[3]   Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer [J].
Burns, LJ ;
Weisdorf, DJ ;
DeFor, TE ;
Repka, TL ;
Ogle, KM ;
Hummer, C ;
Miller, JS .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (01) :96-103
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
Diviné M, 1999, BRIT J HAEMATOL, V105, P349, DOI 10.1046/j.1365-2141.1999.01344.x
[7]  
Ferrandina G, 2003, CLIN CANCER RES, V9, P195
[8]   Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma [J].
Gordan, LN ;
Sugrue, MW ;
Lynch, JW ;
Williams, KD ;
Khan, SA ;
Moreb, JS .
BONE MARROW TRANSPLANTATION, 2003, 31 (11) :1009-1013
[9]   Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation [J].
Guillaume, T ;
Rubinstein, DB ;
Symann, M .
BLOOD, 1998, 92 (05) :1471-1490
[10]   A prognostic score for advanced Hodgkin's disease [J].
Hasenclever, D ;
Diehl, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1506-1514